SCHEMBL20051379

SCHEMBL20051379

Nc1cc(-c2cccc(Br)c2)on1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 4/20 0.49
KMT2A Q03164 4/20 0.49
RAB9A P51151 7/20 0.47
MAPT P10636 3/20 0.47
ALDH1A1 P00352 2/20 0.47
HPGD P15428 1/20 0.47
HK1 P19367 1/20 0.47
HKDC1 Q2TB90 1/20 0.47
NPC1 O15118 6/20 0.44
MAOB P27338 3/20 0.44
MAOA P21397 1/20 0.44
SMN1; SMN2 Q16637 3/20 0.42
TP53 P04637 2/20 0.42
TSHR P16473 1/20 0.42
HSD17B1 P14061 1/20 0.41
HSD17B2 P37059 1/20 0.41
PTPN1 P18031 1/20 0.41
CYP1A2 P05177 1/20 0.41
KDM4E B2RXH2 2/20 0.41
HSD17B10 Q99714 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1796838 0.81 RAB9A (0.60) MEN1KMT2ARAB9AMAPTALDH1A1
SCHEMBL474220 0.79 PTPN1 (0.56) MEN1KMT2ARAB9AMAPTALDH1A1
SCHEMBL1013006 0.79 RAB9A (0.61) MEN1KMT2ARAB9AMAPTALDH1A1
SCHEMBL28658856 0.79 NPC1 (0.72) MEN1KMT2ARAB9AHPGDNPC1
SCHEMBL481400 0.79 HSD17B1 (0.49) MEN1KMT2ARAB9AMAPTALDH1A1
SCHEMBL31607766 0.79 MEN1 (0.52) MEN1KMT2ARAB9AMAPTALDH1A1
SCHEMBL27141380 0.79 MEN1 (0.52) MEN1KMT2ARAB9AMAPTALDH1A1
SCHEMBL16825991 0.79 NPC1 (0.50) RAB9AMAPTALDH1A1NPC1SMN1; SMN2
SCHEMBL30422500 0.79 NPC1 (0.72) MEN1KMT2ARAB9AHPGDNPC1
SCHEMBL11257426 0.76 RAB9A (0.57) MEN1KMT2ARAB9AMAPTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-109803963-B Cyano-substituted heterocycles having USP30 inhibitor activity 特殊治疗有限公司 2022-04-26 CN disclosed
US-20210284631-A1 CYANO-SUBSTITUTED HETEROCYCLES WITH ACTIVITY AS INHIBITORS OF USP30 MISSION THERAPEUTICS LIMITED (GB) 2021-09-16 US disclosed
EP-3523291-B1 CYANO-SUBSTITUTED HETEROCYCLES WITH ACTIVITY AS INHIBITORS OF USP30 MISSION THERAPEUTICS LTD (GB) 2021-04-14 EP disclosed
WO-2018065768-A1 CYANO-SUBSTITUTED HETEROCYCLES WITH ACTIVITY AS INHIBITORS OF USP30 MISSION THERAPEUTICS LIMITED (GB) 2018-04-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210284631-A1 CYANO-SUBSTITUTED HETEROCYCLES WITH ACTIVITY AS INHIBITORS OF USP30 USP30, USP28, USP1 MEN1 3541/4885KMT2A 2651/4885RAB9A 3037/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.